E. R. Squibb Sons, Inc.

Bristol-Myers Squibb Compnay

Other

Patel, Ramesh N.

Szarka, Laszlo J.

Banerjee, Amit

Mcnamee, Clyde G.

Laszlo J Szarka

Ramesh N Patel

Amit Banerjee

Ronald L Hanson

Clyde G McNamee

John K Thottathil

John J Venit

Steven L Goldberg

Jeffrey M Howell

David R Kronenthal

Richard A Partyka

Brian L Davis

Jerome L Moniot

Paul Alan Jass

Venkata B Nanduri

Sushil K Srivastava

Keith Ramig

Shankar Swaminathan

Paul M Cino

Wen-sen Li

David A Lust

Mary Jo Donovan

Robert W Eltz

Richard H Mueller

William John Winter

Robert M Johnston

David B Brzozowski

Gerard Crispino

Neal G Anderson

Thomas P Tully

Robert S Robison

Mark Liu

Raphael Y Ko

Clyde G Mcnamee

The present invention concerns an enzymatic oxidative deamination process of a dipeptide monomer to prepare an intermediate useful to prepare compounds having endopeptidase and angiotensin converting enzyme inhibition activity.

Enzymatic oxidative deamination process

Processes for stereoselective enzymatic conversion of certain keto carboxylic acid derivatives to form the corresponding alkylamino acid compounds are described. The invention also concerns an engineered yeast host cell containing recombinant nucleic acid capable of expressing a phenylalanine dehydrogenase, as well as an engineered host cell containing recombinant nucleic acid capable of expressing a phenylalanine dehydrogenase enzyme and nucleic acid capable of expressing a formate dehydrogenase enzyme.

Stereoselective reductive amination of ketones

An enzymatic reduction method, particularly a stereoselective enzymatic reduction method, for the preparation of halohydrins from haloketones. The halohydrin products are particularly useful in the preparation of epoxides, which may be employed as intermediates in the preparation of protease inhibitors such as retroviral protease inhibitors.

Enzymatic reduction method for the preparation of halohydrins

An enzymatic hydroxylation process for the preparation of compounds useful as HMG-CoA reductase inhibitors and/or as intermediates in the preparation of HMG-CoA reductase inhibitors uses a microorganism or an enzyme derived from, or having the structure of an enzyme derived from, said microorganism, which is capable of catalyzing the hydroxylation process.

Enzymatic hydroxylation process for the preparation of HMG-CoA reductase

A process is described for preparing a compound of the formula or the S-enantiomer thereof, wherein:

Enantioselective preparation of halophenyl alcohols and acylates

Enzymatic hydrolysis and glycosidation methods for the preparation of pradimicin compounds, especially the compound BMY-28960: ##STR1## and salts thereof.

Enzymatic methods for the preparation of pradimicins

Methods for the enzymatic resolution of mixtures of enantiomers, such as .beta.-lactam compounds, which may be employed as intermediates in the preparation of taxanes such as taxol, the latter useful in the pharmaceutical field.

Lipase esterification processes for resolution of enantiomeric mixtures

An enzymatic hydrolysis method for the preparation of compounds useful as intermediates in the preparation of taxanes such as taxol, wherein one or more C-13 acyloxy-bearing taxanes are contacted with an enzyme or microorganism capable of hydrolyzing said acyloxy groups to hydroxyl groups.

Enzymatic hydrolysis method for the preparation of C-13 hydroxyl-bearing

An enzymatic hydrolysis method, wherein one or more C-7 sugar, preferably C-7 xylosyl-bearing taxanes are contacted with an enzyme or microorganism capable of hydrolyzing said sugar groups to hydroxyl groups.

Enzymatic hydrolysis method for the conversion of C-7 sugar to C-7

An enzymatic reduction method, particularly a stereoselective enzymatic reduction method, for the preparation of compounds useful as intermediates in the preparation of taxanes.

Enzymatic reduction method for the preparation of compounds useful for

A process is provided for preparing a substantially optically pure phosphonate ester or phosphonate thioester intermediate via an enzymatically catalyzed enantioselective reaction, which intermediate is employed in preparing phosphonosulfonate squalene synthetase inhibitors.

Process for preparing an optically pure intermediate for a

Enzymatic hydrolysis and esterification processes for the preparation of compounds useful as HMG-CoA reductase inhibitors and/or as intermediates in the preparation of HMG-CoA reductase inhibitors.

Enzymatic hydrolysis and esterification processes for the preparation of

Enzymatic processes for resolution of enantiomeric mixtures of compounds

Growing community of inventors

East Brunswick, NJ, United States of America

Laszlo J Szarka